For example, a recent study generated a T-cell-based therapy that links T cells to cancer cells using a novel antibody that specifically binds to the p53R175H peptide-MHC complex, lysing cancer cells depending on the presence of the neoantigen.379 Clinical studies targeting mutant p53 neoantigens in PCa are rare. Here, TP53 is linked to cancer.